Affimed NV AFMD.OQ, AFMD.O is expected to show a rise in quarterly revenue when it reports results on November 14 for the period ending September 30 2024
The Heidelberg Baden-wuerttemberg-based company is expected to report a 1.9% increase in revenue to €2 million from €1.96 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Affimed NV is for a loss of 94 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Affimed NV is $25.00, above its last closing price of $3.83.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.02 | -0.89 | -1.01 | Missed | -13.1 |
Mar. 31 2024 | -1.53 | -1.43 | -1.27 | Beat | 11.3 |
Dec. 31 2023 | -1.10 | -1.54 | -1.35 | Beat | 12.5 |
Jun. 30 2023 | -1.83 | -1.84 | -1.60 | Beat | 13.1 |
Jun. 30 2023 | -1.90 | -1.90 | -2.00 | Missed | -5.5 |
Mar. 31 2023 | -1.96 | -1.95 | -2.10 | Missed | -7.4 |
Dec. 31 2022 | -1.94 | -1.94 | -2.20 | Missed | -13.2 |
Sep. 30 2022 | -1.80 | -1.76 | -1.10 | Beat | 37.6 |
This summary was machine generated November 8 at 15:32 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。